La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Colambda Technologies Ltd Ordinary Shares a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Colambda Technologies Ltd Ordinary Shares..

Colambda Technologies Ltd Ordinary Shares (OTC:NCRE) Azioni, Catena delle Opzioni

Colambda Technologies Ltd Ordinary Shares

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.20 by 10 percent. This is a 37.93 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $660.30 million which beat the analyst consensus estimate of $650.90 million by 1.44 percent. This is a 3.48 percent increase over sales of $638.10 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand Q1 Adj. EPS $0.18 Misses $0.20 Estimate, Sales $660.30M Beat $650.90M Estimate

On May 1, 2025, the Board of Directors (the "Board") of Pixelworks, Inc. (the "Company") approved a restructuring plan to make the operation of the Company more efficient and which would result in an approximately 4% reduction in workforce, primarily in the area of research and development. The Board and management believe adoption of this restructuring plan will help streamline the Company's operations and workforce, and more appropriately align the Company's operating expenses with current revenue levels. The Company expects the restructuring to be substantially complete by the end of the second quarter ending June 30, 2025 and expects to incur total estimated restructuring charges of approximately $0.6 million related to employee severance and benefits. The Company expects that these charges will largely be recorded in the second quarter of 2025.
 &nbsp;
As a result of the restructuring, the Company expects to realize annualized savings of approximately $2.0 million.

Management

PXLW

Pixelworks Approves Restructuring Plan to Cut 4% of Workforce, Primarily In R&D, Aiming To Streamline Operations, Align Costs With Revenue, And Save $2M Annually With $600K In Severance Charges Expected In Q2 2025

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) lowers FY2025 Adj EPS guidance from $1.40-$1.57 to $1.03-$1.32 vs $1.46 analyst estimate..

Guidance

MasterBrand Lowers FY2025 Adj EPS Guidance from $1.40-$1.57 to $1.03-$1.32 vs $1.46 Est

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.34 by 44.12 percent. This is a 83.28 percent decrease over earnings of $2.93 per share from the same period last year. The company reported quarterly sales of $910.40 million which missed the analyst consensus estimate of $947.79 million by 3.95 percent. This is a 13.83 percent decrease over sales of $1.06 billion the same period last year.

Hyster Yale Q1 Adj. EPS $0.49 Beats $0.34 Estimate, Sales $910.40M Miss $947.79M Estimate

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) affirms FY2025 sales outlook from $445.00 million-$470.00 million to $445.00 million-$470.00 million vs $460.02 million estimate.

NATR

Natures Sunshine Products Affirms FY2025 Sales Guidance of $445.00M-$470.00M vs $460.02M Est

WIIM

OPEN

Opendoor Technologies shares are trading higher after the company reported better-than-expected Q1 financial results.

SNTI

Senti Biosciences Q1 EPS $(1.41) Up From $(2.60) YoY

Powell Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) reported quarterly earnings of $3.81 per share which beat the analyst consensus estimate of $3.44 by 10.76 percent. This is a 38.55 percent increase over earnings of $2.75 per share from the same period last year. The company reported quarterly sales of $278.63 million which missed the analyst consensus estimate of $282.68 million by 1.43 percent. This is a 9.22 percent increase over sales of $255.11 million the same period last year.

POWL

Powell Industries Q2 EPS $3.81 Beats $3.44 Estimate, Sales $278.63M Miss $282.68M Estimate

KLIC

Kulicke and Soffa Industries shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 guidance below estimates.

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.17 by 47.06 percent. This is a 108.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $113.25 million which beat the analyst consensus estimate of $109.39 million by 3.53 percent. This is a 2.03 percent increase over sales of $110.99 million the same period last year.

Natures Sunshine Products Q1 Adj. EPS $0.25 Beats $0.17 Estimate, Sales $113.25M Beat $109.39M Estimate

Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) ("Transcat" or the "Company"), a leading provider of mission critical calibration services and distributor of test and measurement equipment to Fortune 500 Manufacturers, today announced it has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets.
MZ Group will work closely with Transcat management to develop and implement a comprehensive Investor and Media Relations strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Transcat's market-leading position providing mission critical, accredited calibration services and equipment to a blue-chip client base, with the footprint and scale to support large national opportunities. Since 1964, clients served include a diverse set of industries in life sciences, aerospace and government/defense.

TRNS

Transcat Announces It Has Engaged International Investor Relations Specialists MZ Group To Lead A Comprehensive Strategic Investor Relations And Financial Communications Program Across All Key Markets

Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported financial results for the first quarter after the market close on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/05/n45235468/lucid-announces-first-quarter-2025-financial-results">from the quarter</a>.
Q1 Earnings: Lucid reported first-quarter revenue of $235.05 million, missing <a href="https://www.benzinga.com/quote/LCID/earnings">analyst estimates</a> of $250 million, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The electric vehicle maker reported a first-quarter loss of 20 cents per share, beating analyst estimates for a loss of 23 cents per share.
Lucid said it produced 2,212 vehicles in the first quarter and delivered 3,109 vehicles.&nbsp;The production number doesn&#8217;t include more than 600 vehicles in transit to Saudi Arabia for factory gating. 
The company ended the quarter with approximately $5.76 billion in total liquidity.
&#8220;We continued to build momentum in the&nbsp;first quarter&nbsp;as we achieved yet another delivery record, further strengthened our market position, and executed against operational priorities,&#8221; said&nbsp;Marc Winterhoff, interim CEO of Lucid. 
&#8220;Lucid Gravity is beginning to arrive in more customers&#8217; driveways and at our studios, and combined with our progress toward future initiatives, our company is well-positioned for future success.&#8221;
Outlook: Lucid continues to expect total production of approximately 20,000 vehicles in 2025.
&#8220;We&#8217;re executing against our near-term goals — driving volume, improving margins and operating with rigor. And we&#8217;re positioning ourselves for long-term value creation — with clear strategic priorities, strong liquidity and breakthrough products that redefine their categories,&#8221; said Taoufiq Boussaid, CFO of Lucid.
Lucid executives will hold a conference call at 5:30 p.m. ET to further discuss details from the first quarter.
LCID Price Action:&nbsp;<a href="http://benzinga.com/quote/lcid" target="_blank" rel="noreferrer noopener">Lucid shares</a>&nbsp;were up 0.43% in after-hours, trading at $2.34 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/25/05/45218458/rivian-handed-16-million-boost-by-government-as-plans-for-120-million-illinois-supplier-park-take-shape">Rivian To Receive $16 Million Incentive As Plans For $120 Million Illinois Supplier Park Take Shape</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/25/05/45205881/lucid-q1-earnings-preview-lower-priced-gravity-tariff-concerns-market-share-gains-from-tesla-top-items-to-watch">Lucid Q1 Earnings Preview: Lower-Priced Vehicles, Tariff Concerns, Market Share Gains From Tesla, Top Items To Watch</a></li>
</ul>
Photo: Courtesy of Lucid.

Topics

After-Hours Center

Movers

LCID

Lucid Q1 Earnings: Revenue Miss, Smaller-Than-Expected Loss, EV Maker Reaffirms FY25 Production Guidance Of 20,000 Vehicles

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) sees Q2 sales of $65.000 million-$67.000 million vs $65.57 million analyst estimate.

LFMD

LifeMD Sees Q2 Sales $65.000M-$67.000M vs $65.57M Est

Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) traded lower on Tuesday after the company&#8217;s Q1 earnings <a href="https://www.benzinga.com/pressreleases/25/05/g45206366/tactile-systems-technology-inc-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">missed Wall Street expectations on Monday</a>.
The medical technology company reported adjusted loss per share of 13 cents, down from a loss of 9 cents a year ago, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">missing the consensus of 7 cents</a>.
Total revenue in the first quarter of 2025 increased 0.3% to $61.27 million, missing the consensus of $63.28 million.
The increase was attributable to a 22% increase in sales of the airway clearance product line, offset by a decrease of $1.8 million, or 3%, in sales and rentals of the lymphedema product line.
Gross profit increased 4% to $45.3 million. Gross margin was 74% of revenue, compared to 71% in the first quarter of 2024. The increase in gross profit was primarily attributable to lower manufacturing and warranty costs.
Adjusted EBITDA loss was $0.3 million in the first quarter of 2025, compared to positive Adjusted EBITDA of $1.0 million in the first quarter of 2024.
&#8220;Through the first quarter our team executed on several highly strategic, growth-oriented priorities. We launched Nimbl for lower extremity lymphedema, completed efforts to optimize our sales organization for scale and efficiency, and implemented a new CRM tool,&#8221; said Sheri Dodd, CEO of Tactile Medical.
&#8220;While these efforts have had a temporary impact on sales force productivity, we are thrilled with the progress made and firmly believe these transformational actions are essential to positioning Tactile for consistent, long-term growth. Our underlying business fundamentals remain firmly in place, and we are meaningfully advancing each of our three 2025 strategic priorities to remain the competitive market share leader in medical device lymphatic therapy,&#8221; Dodd added.
Guidance: Tactile Systems lowered its fiscal 2025 sales guidance from $316 million-$322 million to $309 million-$315 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45206366/tactile-systems-technology-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">versus consensus of $317.91 million</a>.
The company now also expects a full-year 2025 adjusted EBITDA of $32 million to $34 million, compared to an adjusted EBITDA of $37.1 million in 2024. The company&#8217;s prior 2025 guidance expectation was adjusted EBITDA in the range <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43796909/tactile-systems-technology-inc-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">of $35 million to $37 million</a>.
William Blair analyst Margaret Kaczor Andrew writes, &#8220;Despite the larger headwind seen in the quarter, management is already starting to see the metrics turn more positive, having nearly recovered to end-of-year headcount levels, recording positive April metrics, and seeing growth in referrals despite a decrease in feet on the street&#8230;Though the company has had a series of headwinds that offset its tailwinds over the last year, and as such it may take some time for investors to regain confidence in the outlook, we see a number of catalysts that should turn positive in the coming quarters and drive traction in shares.&#8221;
&#8220;Despite the weakness this quarter, we continue to believe that the investments made throughout the year should position Tactile favorably over the medium to long-term,&#8221; Kaczor Andrew adds.
William Blair maintains <a target="_blank" href="https://www.benzinga.com/quote/TCMD/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Piper Sandler downgraded Tactile Systems from Overweight to Neutral, lowering the price target from $25 to $14.
Price Action: TCMD stock was down 28.9% to $9.90 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45221705/doordash-is-hungry-for-growth-q1-orders-jump-18-plans-2-big-acquisitions-to-expand-international-presence" target="_blank" rel="noreferrer noopener">DoorDash Is Hungry For Growth: Q1 Orders Jump 18%, Plans 2 Big Acquisitions To Expand International Presence</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Analyst Ratings

Trading Ideas

General

TCMD

Tactile Systems Stock Tumbles As Q1 Earnings Fall Short Of Expectations

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) raises FY2025 sales outlook from $265.00 million-$275.00 million to $268.00 million-$275.00 million vs $268.86 million estimate.

LifeMD Raises FY2025 Sales Guidance from $265.00M-$275.00M to $268.00M-$275.00M vs $268.86M Est

ATRO

Astronics shares are trading higher after the company reported better-than-expected Q1 financial results.

Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) sees Q2 sales of $225.000 million-$235.000 million.

INVX

Innovex International Sees Q2 Sales $225.000M-$235.000M

Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.32 by 34.38 percent. The company reported $240.41 million in sales this quarter.

Innovex International Q1 Sales $240.41M

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.05) by 120 percent. This is unchanged from the same period last year. The company reported quarterly sales of $65.70 million which beat the analyst consensus estimate of $62.55 million by 5.03 percent. This is a 48.83 percent increase over sales of $44.14 million the same period last year.

Comments

Colambda Technologies Ltd Ordinary Shares

Colambda Technologies Ltd Ordinary Shares (NCRE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO